Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$72.66 ▼ -0.05
(-0.07%)
MKT CAP: $11.40B • VOL: 2.57M
52W L $43 52W H $73
TECH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.22B | $1.16B | $1.14B |
| YoY Revenue Growth % | +5.2% | +2.0% | — |
| Gross Profit | $790.3M | $769.7M | — |
| Gross Margin % | 64.8% | 66.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $102.3M | $206.7M | $298.9M |
| Operating Margin % | 8.4% | 17.8% | 26.3% |
| Net Income (GAAP) | $73.4M | $168.1M | $285.3M |
| EBITDA (Normalized) | $127.1M | $257.0M | $339.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $287.6M | $299.0M | $254.4M |
| Capital Expenditures (CapEx) | $31.0M | $62.9M | $51.2M |
| Free Cash Flow (FCF) | $256.6M | $236.1M | $203.2M |
| FCF Margin % | 21.0% | 20.4% | 17.9% |
| Return on Invested Capital (ROIC %) | 3.3% | 6.5% | 6.2% |
| Cash & Short-Term Equivalents | $172.9M | $177.5M | — |
| Total Debt (Short + Long Term) | $590.3M | $624.9M | $1.47B |
| Total Stockholders' Equity | $2.01B | $2.08B | $3.01B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TECH.